On the heels of PRA Health Sciences filing for an IPO, Dan Stanton of Outsourcing-Pharma spoke to many industry experts, including our own VP of Clinical Development, Mark Shapiro, about whether CROs going public suggests a booming market or waning interest from private equity (PE) investors.
Mark points out in his interview with Dan that there has been a great deal of PE investment in the sector. In theory, this could have potentially caused opportunities to dry up. However, Mark suggests there could be more IPOs from PE-backed CROs coming in the next five years—as long as the equities market remains favorable.
To read the Outsroucing-Pharma article in its entirety, click here.
You might also be interested in a related blog post Mark authored regarding the role of PE investments in the CRO industry. In his post, Mark dissects the role PE has played in the industry, why PE firms and CROs have benefitted from long-term relationships, and what their partnerships mean for sponsors.